Anzeige
Mehr »
Login
Samstag, 29.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien
Ad-hoc-News: Wieder Verdopplung? Montag massiver Turnaround und komplette Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EG5 | ISIN: US49721T5074 | Ticker-Symbol: 7EY
NASDAQ
28.03.25
18:37 Uhr
3,090 US-Dollar
+0,070
+2,32 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KIORA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KIORA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur KIORA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiKiora Pharmaceuticals GAAP EPS of $0.87 beats by $0.01, revenue of $16.02M misses by $0.75M3
DiKiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027137Encinitas, California--(Newsfile Corp. - March 25, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2024 financial results and provided an update on...
► Artikel lesen
DiKIORA PHARMACEUTICALS INC - 8-K, Current Report5
DiKIORA PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans2
DiKIORA PHARMACEUTICALS INC - 10-K, Annual Report2
12.03.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting176Encinitas, California--(Newsfile Corp. - March 12, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO-104 in a proliferative...
► Artikel lesen
KIORA PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.02.Kiora Pharmaceuticals sichert sich neues Patent für KIO-1047
13.02.Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104201Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter...
► Artikel lesen
11.02.Kiora Pharmaceuticals, Inc.: Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema278Encinitas, California--(Newsfile Corp. - February 11, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate KLARITY...
► Artikel lesen
15.01.KIORA PHARMACEUTICALS INC - 8-K, Current Report1
08.11.24Kiora Pharmaceuticals GAAP EPS of -$0.81 misses by $0.059
08.11.24Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies444Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided...
► Artikel lesen
08.11.24KIORA PHARMACEUTICALS INC - 8-K, Current Report2
08.11.24KIORA PHARMACEUTICALS INC - 10-Q, Quarterly Report2
29.10.24Kiora Pharmaceuticals gets approval to initiate mid-stage trial for eye disorder treatment3
29.10.24Kiora Pharmaceuticals schreitet mit Phase-2-Studie zur Wiederherstellung des Sehvermögens voran7
29.10.24Kiora Pharmaceuticals advances phase 2 trial for vision restoration2
29.10.24KIORA PHARMACEUTICALS INC - 8-K, Current Report3
29.10.24Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa264Encinitas, California--(Newsfile Corp. - October 29, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it received regulatory approval to initiate a Phase...
► Artikel lesen
25.09.24Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences474Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences....
► Artikel lesen
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1